Endogenous p53 Protein Generated from Wild-Type Alternatively Spliced p53 RNA in Mouse Epidermal Cells

REFERENCES

• Arai, N., D. Nomura, K. Yokota, D. Wolf, E. Brill, O. Shohat, and V. Rotter. 1986. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol. 6:3232–3239.
   PubMedGoogle Scholar
• Balmain, A., R. Krumlauf, J. K. Vass, and G. D. Birnie. 1982. Cloning and characterization of the abundant cytoplasmic 7S RNA from mouse cells. Nucleic Acids Res. 10:4259–4277.
   PubMedGoogle Scholar
• Bargonetti, J., I. Reynisdottir, P. N. Friedman, and C. Prives. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6:1886–1898.
   PubMed Web of Science ®Google Scholar
• Bischoff, J. R., D. Casso, and D. Beach. 1992. Human p53 inhibits growth in Schizosaccharomyces pombe. Mol. Cell. Biol. 12:1405–1411.
   PubMed Web of Science ®Google Scholar
• Burns, P. A., C. J. Kemp, J. V. Gannon, D. P. Lane, R. Bremner, and A. Balmain. 1991. Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene 6:2363–2369.
   PubMedGoogle Scholar
• Clarke, C. F., K. Cheng, A. B. Frey, R. Stein, P. W. Hinds, and A. Levine. 1988. Purification of complexes of nuclear oncogene p53 with rat and Escherichia coli heat shock proteins: in vitro dissociation of hsc70 and dnaK from murine p53 by ATP. Mol. Cell. Biol. 8:1206–1215.
   PubMed Web of Science ®Google Scholar
• Crook, T., C. Fisher, and K. H. Vousden. 1991. Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J. Virol. 6:505–510.
   Google Scholar
• Davies, R., R. E. Edwards, J. A. Green, R. F. Legg, R. T. Snowden, and M. M. Manson. 1993. Antioxidants can delay liver cell maturation which in turn affects γ-glutamyltranspeptidase expression. Carcinogen 14:47–52.
   PubMed Web of Science ®Google Scholar
• Eliyahu, D., N. Goldfinger, O. Pinhasi-Kimhi, G. Shaulsky, Y. Skurnik, N. Arai, V. Rotter, and M. Oren. 1988. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3:313–321.
   PubMed Web of Science ®Google Scholar
• Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature (London) 358:83–86.
   PubMed Web of Science ®Google Scholar
• Finlay, C. A., P. W. Hinds, and A. J. Levine. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093.
   PubMed Web of Science ®Google Scholar
• Fontoura, B. M. A., E. A. Sorokina, E. David, and R. B. Carroll. 1992. p53 is covalently linked to 5.8S rRNA. Mol. Cell. Biol. 12:5145–5151.
   PubMed Web of Science ®Google Scholar
• Foord, O. S., P. Bhattacharya, Z. Reich, and V. Rotter. 1991. A DNA binding domain contained in the C-terminus of wild type p53 protein. Nucleic Acids Res. 19:5191–5198.
   PubMedGoogle Scholar
• Foulkes, N. S., and P. Sassone-Corsi. 1992. More is better: activators and repressors from the same gene. Cell 68:411–414.
   PubMed Web of Science ®Google Scholar
• Hainaut, P., and J. Milner. 1992. Interaction of heat-shock protein 70 with p53 translated in vitro evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. EMBO J. 11:3513–3520.
   PubMed Web of Science ®Google Scholar
• Han, K.-A., and M. F. Kulesz-Martin. 1992. Altered expression of wild-type p53 tumor suppressor gene during murine epithelial cell transformation. Cancer Res. 52:749–753.
   PubMedGoogle Scholar
• Han, K.-A., and M. F. Kulesz-Martin. 1992. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucleic Acids Res. 20:1979–1981.
   PubMedGoogle Scholar
• Han, K.-A., P. Rothberg, and M. Kulesz-Martin. 1990. Altered levels of endogenous retrovirus-like sequence (VL30) RNA during mouse epidermal cell carcinogenesis. Mol. Carcinog. 3:75–82.
   PubMedGoogle Scholar
• Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875–886.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304–6311.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597.
   PubMed Web of Science ®Google Scholar
• Kulesz-Martin, M. Unpublished data.
   Google Scholar
• Kulesz-Martin, M., L. Blumenson, K. F. Manly, J. Siracky, and C. J. East. 1991. Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid. Cancer Res. 51:4701–4706.
   PubMedGoogle Scholar
• Kulesz-Martin, M., A. E. Kilkenny, K. A. Holbrook, V. Digernes, and S. H. Yuspa. 1983. Properties of carcinogen altered mouse epidermal cells resistant to calcium-induced terminal differentiation. Carcinog. 4:1367–1377.
   PubMedGoogle Scholar
• Kulesz-Martin, M., P. Kozlowski, I. Glurich, B. Lisafeld, E. Hemedinger, and V. Kumar. 1989. Pemphigoid, pemphigus and desmoplakin as antigenic markers of differentiation in normal and tumorigenic mouse keratinocyte lines. Cell Tissue Kinet. 22:279–290.
   PubMedGoogle Scholar
• Kulesz-Martin, M. F., L. Blumenson, and B. Lisafeld. 1986. Retinoic acid enhancement of an early step in the transformation of mouse epidermal cells in vitro. Carcinog. 7:1425–1429.
   PubMedGoogle Scholar
• Kulesz-Martin, M. F., M. Yoshida, L. Prestine, S. H. Yuspa, and J. S. Bertram. 1985. Mouse cell clones for improved quantitation of carcinogen-induced altered differentiation. Carcinog. 6:1245–1254.
   PubMedGoogle Scholar
• Lane, D. P. 1992. p53, guardian of the genome. Nature (London) 358:15–16.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Y. Wu, and M. Kulesz-Martin. Unpublished data.
   Google Scholar
• Milne, D. M., R. H. Palmer, and D. W. Meek. 1992. Mutation of the casein kinase II phosphorylation site abolishes the antiproliferative activity of p53. Nucleic Acids Res. 20:5565–5570.
   PubMedGoogle Scholar
• Milner, J. 1984. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature (London) 20:143–145.
   Google Scholar
• Milner, J. 1991. The role of p53 in the normal control of cell proliferation. Curr. Opin. Cell Biol. 3:282–286.
   PubMed Web of Science ®Google Scholar
• Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765–774.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Nigro, J. M., R. Sikorski, S. I. Reed, and B. Vogelstein. 1992. Human p53 and CDC2Hs genes combine to inhibit the proliferation of Saccharomyces cerevisiae. Mol. Cell. Biol. 12:1357–1365.
   PubMed Web of Science ®Google Scholar
• Oren, M., and A. J. Levine. 1983. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc. Natl. Acad. Sci. USA 80:56–59.
   PubMed Web of Science ®Google Scholar
• Prives, C., and J. J. Manfredi. 1993. The p53 tumor suppressor protein: meeting review. Genes Dev. 7:529–534.
   PubMed Web of Science ®Google Scholar
• Ro, Y. S., P. N. Cooper, J. A. Lee, A. G. Quinn, D. Harrison, D. Lane, C. H. W. Horne, J. L. Rees, and B. Angus. 1993. p53 protein expression in benign and malignant skin tumours. Br. J. Dermatol. 12:237–241.
   Google Scholar
• Ruggeri, B., J. Caamano, T. Goodrow, M. DiRado, A. Bianchi, D. Trono, C. J. Conti, and J. P. Klein-Szanto. 1991. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res. 51:6615–6621.
   PubMedGoogle Scholar
• Schneider, B. L., G. T. Bowden, C. Sutter, J. Schweizer, K.-A. Han, and M. Kulesz-Martin. 1993. 7,12-Dimethylbenz[a]anthracene- induced mouse keratinocyte transformation without Harvey ras protooncogene mutations. J. Invest. Dermatol. 101:595–599.
   PubMedGoogle Scholar
• Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89:12028–12032.
   PubMed Web of Science ®Google Scholar
• Soussi, T., C. Caron deFromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945–952.
   PubMed Web of Science ®Google Scholar
• Stenger, J. E., G. A. Mayr, K. Mann, and P. Tegtmeyer. 1992. Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinog. 5:102–106.
   PubMedGoogle Scholar
• Stephen, C. W., and D. P. Lane. 1992. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J. Mol. Biol. 225:577–583.
   PubMed Web of Science ®Google Scholar
• Sturzbecher, H. S., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal α-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513–1523.
   PubMedGoogle Scholar
• Vogelstein, B. 1990. A deadly inheritance. Nature (London) 348:681–682.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.
   PubMed Web of Science ®Google Scholar
• Wade-Evans, A., and J. R. Jenkins. 1985. Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J. 4:699–706.
   PubMed Web of Science ®Google Scholar
• Weintraub, H., S. Hauschka, and S. J. Tapscott. 1991. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA 88:4570–4571.
   PubMed Web of Science ®Google Scholar
• Wolf, D., N. Harris, N. Goldfinger, and V. Rotter. 1985. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol. Cell. Biol. 5:127–132.
   PubMedGoogle Scholar
• Wolf, D., N. Harris, and V. Rotter. 1984. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 38:119–126.
   PubMed Web of Science ®Google Scholar
• Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:444–452.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach, E., D. Grunwald, S. Wilder, A. Kimchi, E. May, J.-J. Lawrence, P. May, and M. Oren. 1993. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol. 13:1415–1423.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach, E., D. Resnitzky, J. Lotem, D. Michael, L. Sachs, A. Kimchi, and M. Oren. 1992. Induction of apoptosis (programmed cell death) by wild-type p53, p. 201–211. In D. M. Livingston, and E. M. Mihich (ed.), Tumor suppressor genes. Pezcoller Foundation Symposium 3. Edigraf, s.r.l., Rome.
   Google Scholar
• Zambetti, G. P., J. Bargonetti, K. Walker, C. Prives, and A. J. Levine. 1992. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6:1143–1152.
   PubMed Web of Science ®Google Scholar